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Poster Session-II 113whom 10 were identified with PI. Symptoms ranged from none to
abdominal pain, abdominal distention, cough and respiratory
distress. Diagnosis was established by CT scan (n 5 7), plain film
(n5 2) or colonoscopy (n5 1). Nine of 10 pts had ongoing GI graft
versus host disease (GvHD) at diagnosis or a recent history of treat-
ment for GI GvHD. Prior to 04/02, 2 pts underwent subtotal colec-
tomy with ileostomy (n5 1) and sigmoid colectomy with colostomy
(n 5 1). One pt was managed with bowel rest and total parental
nutrition (TPN) only. These 3 pts died 0.4, 1.1, and 3.9 years after
PI diagnosis due to GI GvHD (n5 2) and surgical complications af-
ter colostomy revision (n 5 1). Seven PI pts diagnosed after 09/06
were treated with GI rest, TPN and oral antibiotics (rifaximin,
augmentin and metronidazole) to decrease anaerobic bowel flora.
Median duration of antibiotic use was 47 days (range:26–1361,
one pt was still on antibiotics as of last follow up on 10/3/08), median
duration of TPN was 41 days (range:25–64) and median duration of
GI rest was 23 days (range:3–34). On this regimen, all 7 patients had
resolution of PI at a median time of 36 days (range:10–70). Of the 7
pts, 5 died due to GI GvHD (n5 3), relapsed disease (n5 1) or pre-
existing diverticulitis (n 5 1) at 0.92, 0.46, 0.07, 0.15, and 1.3 years
after PI diagnosis. PI pts treated with GI rest, TPN and oral antibi-
otics may have resolution of PI. In most cases it is a non-critical find-
ing that does not represent true GI tract ischemia and/or GI tract
perforation. Non-surgical management of PI with therapy directed
against anaerobic bacteria may result in complete resolution.313
USE OF PALIFERMIN IN ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
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Background: Palifermin is a recombinant keratinocyte growth
factor (KGF) approved to decrease the incidence and severity of
mucositis in stem cell transplantation. Furthermore, effects on the
KGF receptor may modulate and minimize acute GVHD. Studies
utilizing palifermin have been conducted in autologous SCT; how-
ever, literature regarding use in allogeneic SCT is minimal.
Methods:We evaluated time to engraftment, incidence/duration
of mucositis, and incidence of acute GVHD in 22 ALL patients (15
M/7 F) treated from 2004 to 2008 with 12GyTBI, etoposide 60mg/
kg, and unmanipulated cells. Seven patients received weekly rituxi-
mab at 375 mg/m2 x 4 doses as part of a study. GVHD prophylaxis
consisted of mini-dose methotrexate and tacrolimus. Anti-
thymocyte-globulin was added to matched unrelated patients.
Patients also received 3 daily doses of palifermin 60 mcg/kg preced-
ing initiation of chemotherapy, and following stem cell infusion.
Outcomes were compared to a historical control group of 19 ALL
patients (12 M/7 F) treated with a TBI-based preparative regimen
who did not receive palifermin.
Results: The median age in the palifermin arm was 36.5 years
(19–51) versus 34 years (16–52) in the historical arm. Donor type
was matched related or matched unrelated in 12 and 10 patients,
respectively, in the palifermin arm versus 11 and 8 patients, respec-
tively, in the historical arm. All patients in palifermin and historical
control groups developed mucositis. The median duration of muco-
sitis was 13 days (3–28) in the historical arm and 14 days (3–27) in the
palifermin arm. Patient-controlled analgesia was used in 14 patients
for a median of 13.5 days in the historical arm versus 17 patients for
a median of 13 days in the palifermin arm. Median time to ANC $
0.5  109/L was 15 days (12–26) for the palifermin arm versus 14
days (12–26) for the historical arm; median time to platelet count
$ 20  109/L was 15 days (6–30) for the palifermin arm and 13
days (5–37) for the historical arm. The incidence of grades II-IV
and III-IV acute GVHD were 18% (n5 4) and 5% (n5 1), respec-
tively, in the palifermin arm versus 32% (n 5 6) and 11% (n 5 2),
respectively, in the historical arm.
Conclusions: Palifermin use for allogeneic SCT is feasible with
no impact on engraftment, and possibly reduction in acute
GVHD. However, we failed to detect reduction of mucositis with
palifermin use. Our observations are limited by the retrospective na-
ture of the comparisons and small patient numbers.314
FEASIBILITY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION (ALLO-SCT) FOLLOWING REDUCED INTENSITY CONDITION-
ING (RIC) IN HIV1 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Hamadani, M., Baiocchi, R., Lin, T., Blum, K.A., Ezzone, S.,
Benson DM Jr., Jr., Devine, S.M. Arthur G. James Comprehensive Can-
cer Center, the Ohio State University, Columbus, OH
The role of RIC Allo-SCT in HIV1 patients with hematological
malignancies remains to be defined. We employed a uniform strat-
egy of RIC consisting of fludarabine (30 mg/m2/day, days 27 to
23), busulfan (0.8 mg/kg/dose IV 8 doses) with (n5 2) or without
(n5 1) (6mg/kg) rabbit ATG in three HIV1 patients with hemato-
logical malignancies. Median patient age was 51 yrs (range 39–55
yrs). One patient each had AML, Burkitt’s lymphoma and plasma-
blastic lymphoma. All patients were in CR2 at the time of transplan-
tation. Median pre-transplant (preT) CD4 count was 339cells/uL
(range 189–457cells/uL). 2 patients had undetectable HIV viral
load preT, while it was 814copies/ml in the third patient. All patients
had HCI-comorbidity index of$3. Donors included sibling (n5 1)
or unrelated volunteers (n5 2). GVHDprophylaxis consisted of mi-
cro-dose methotrexate and tacrolimus. HAART was not interrupted
during or after transplantation. All patients engrafted promptly
following transplantation. Only one patient developed transient
stage III cutaneous acute GVHD.While one patient each developed
extensive and limited chronic GVHD. At a median follow-up of 375
days (range 71–526 days) all patients are alive, with no evidence of
disease relapse. Post-transplant HIV viral load remains undetectable
in 2 patients. In the third patient mildly elevated HIV viral load
(2000copies/ml) on day 1252, promptly became undetectable with
second line HAART. Similarly the CD4 count remained
.200cell/uL at all measurements post-transplantation. Chimerism
analysis showed 100% donor CD331 chimerism at all time points
(days 30, 90, 180 and 1365) and median donor CD31 chimerism
of 90%, 84%, and 100% at days130, 1180 and1365. One patient
developed CMV reactivation which responded to preemptive antivi-
ral therapy.No patients developed anyHIV related opportunistic in-
fections. This case series provides critical preliminary evidence that
RIC Allo-SCT with concurrent uninterrupted HAART is safe and
feasible in HIV1 patients with malignant hematological disorders.315
A SINGLE APHERESIS PROCEDURE IN THE DONOR MAY BE ENOUGH TO
COMPLETE AN ALLOGRAFT USING THE ‘‘MEXICAN METHOD’’ OF NON-
ABLATIVE ALLOGRAFTING
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We have analyzed the salient apheresis features of a group of 175
allogeneic peripheral blood stemcell transplants conducted in two in-
stitutions in a seven-year period.The graftswere conducted using the
‘‘Mexican’’ non-myeloablative conditioning regimen employing oral
busulphan, iv cyclophosphamide and iv fludarabine. In all instances,
the apheresis machine employed was the Baxter CS3000 Plus and
donors were mobilized with filgrastim. The apheresis procedures
were performed on days24,23, and – 2, the endpoint of collection
being 5 000 ml of blood / m2 in each procedure. Three apheresis ses-
sions were planned but the number was adjusted according to the cell
yield.The final number of allograftedCD34 cells ranged between 0.5
and 25.4 106/Kg of the recipient (median 5.2  106/Kg). One to 3
apheresis procedures were needed to accomplish a product contain-
ing above 0.5 106/Kg of the recipientCD34 cells, themedian being
2 procedures; in 72 cases (41%) a single apheresis procedure was
enough to obtain the target number of CD34 cells. The apheresis
products volumes ranged between 50 and 600ml (median 400). Since
the median cost of each apheresis procedure is 900 USD, the cost of
two apheresis procedures was spared in 72 procedures, whereas the
cost of one was spared in 65, thus making an approximate total
amount of 188 100 USD saved. It is concluded that allogeneic trans-
plants can be completed using a single apheresis session and that con-
siderable economic consequences can be derived from this practice.
